Yan Gong, Ph.D.
Associate Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6297
Business Email:
gong@cop.ufl.edu
About Yan Gong
Yan Gong, Ph.D., is an Associate Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida (UF) College of Pharmacy and the UF Center for Pharmacogenomics and Precision Medicine. Dr. Gong received a Ph.D. in Pharmaceutics in 2004 from Department of Pharmaceutics, College of Pharmacy at UF. She also obtained a Master’s Degree in Statistics in 2003 from UF Department of Statistics. Before joining the UF faculty in 2005, she completed one year of post-doctoral Fellowship in Cardiovascular Pharmacogenomics at the UF Center for Pharmacogenomics.
Dr. Gong’s research focuses on pharmacogenomics of efficacy and adverse response of antihypertensives medications, and pharmacogenomics of serious adverse drug events such as medication-related osteonecrosis of the jaw (MRONJ) and cardiotoxicities related to cancer therapies (Cardio-Oncology). Dr. Gong has authored over 170 peer-reviewed publications.
In addition to research, Dr. Gong has been involved in teaching multiple graduate level and professional level courses at the UF College of Pharmacy and College of Medicine. She is currently the course co-coordinator for Pharmacogenomic and Genomic Data Analysis (PHA6449), a required graduate level course for the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy.
Teaching Profile
Courses Taught
2019-2020,2022-2023
PHA7979 Advanced Research
2020
PHA7980 Research for Doctoral Dissertation
2020-2021
PHA7939 Journal Colloquy in Pharmacodynamics
2020-2023
PHA6910 Supervised Research
2012,2014-2016,2016-2020,2018-2022,2020-2022,2022
PHA6449 Pharmacogenomics
2010-2015
PHA5719 Intro Quant Methods
2014
PHA5907 Research in Phar Prac
2021
PHA6935 Selected Topics in Pharmacy
2021-2022
PHA7900 Journal Club in Pharmaceutical Research
2022
PHA6971 Research for Master’s Thesis
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-8218-1620
Publications
2023
Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
Journal of the American Heart Association.
12(12)
[DOI] 10.1161/jaha.123.029361.
2023
Evaluation of Potential Racial Disparities in CYP2C19‐Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention
Clinical Pharmacology & Therapeutics.
113(3):615-623
[DOI] 10.1002/cpt.2776.
[PMID] 36306392.
2023
Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline‐Based Chemotherapy
Journal of the American Heart Association.
12(10)
[DOI] 10.1161/jaha.122.027981.
2023
Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma.
Frontiers in cardiovascular medicine.
10
[DOI] 10.3389/fcvm.2023.1181806.
[PMID] 37408649.
2022
Medication‐Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium
Journal of Bone and Mineral Research.
37(12):2466-2471
[DOI] 10.1002/jbmr.4708.
[PMID] 36151778.
2022
A randomized, cross‐over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence
Clinical and Translational Science.
15(7):1764-1775
[DOI] 10.1111/cts.13294.
[PMID] 35488487.
2022
Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death in Cancer Survivors.
JAMA network open.
5(6)
[DOI] 10.1001/jamanetworkopen.2022.18183.
[PMID] 35731518.
2022
Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis.
Frontiers in physiology.
13
[DOI] 10.3389/fphys.2022.909870.
[PMID] 35812313.
2022
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials.
Hematological oncology.
40(2):233-242
[DOI] 10.1002/hon.2959.
[PMID] 34940983.
2022
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.
Genes.
13(7)
[DOI] 10.3390/genes13071260.
[PMID] 35886043.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics.
112(1):146-155
[DOI] 10.1002/cpt.2612.
[PMID] 35429163.
2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators
Clinical and Translational Science.
15(10):2479-2492
[DOI] 10.1111/cts.13376.
[PMID] 35899435.
2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
Metabolites.
12(9)
[DOI] 10.3390/metabo12090783.
[PMID] 36144188.
2021
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(4):621-628
[DOI] 10.1038/s41436-020-01050-4.
[PMID] 33420349.
2021
Adverse Cardiovascular Outcomes and Antihypertensive treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS).
Clinical pharmacology and therapeutics.
[DOI] 10.1002/cpt.2355.
[PMID] 34231218.
2021
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
JAMA network open.
4(4)
[DOI] 10.1001/jamanetworkopen.2021.8418.
[PMID] 33914047.
2021
Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
Clinical and Translational Science.
14(1):36-46
[DOI] 10.1111/cts.12857.
[PMID] 32770710.
2021
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.
European heart journal.
42(18):1742-1756
[DOI] 10.1093/eurheartj/ehab107.
[PMID] 33748830.
2021
Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw.
Clinical pharmacology and therapeutics.
110(6):1558-1569
[DOI] 10.1002/cpt.2397.
[PMID] 34390503.
2021
Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Clinical and translational science.
14(2):492-496
[DOI] 10.1111/cts.12939.
[PMID] 33278335.
2021
Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
Frontiers in cardiovascular medicine.
8
[DOI] 10.3389/fcvm.2021.645122.
[PMID] 33996940.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites.
11(9)
[DOI] 10.3390/metabo11090645.
[PMID] 34564461.
2021
Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.
Cardio-oncology (London, England).
7(1)
[DOI] 10.1186/s40959-021-00097-9.
[PMID] 33736707.
2021
Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing.
Clinical and translational science.
14(2):617-624
[DOI] 10.1111/cts.12922.
[PMID] 33142006.
2021
Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
92
[DOI] 10.1016/j.meegid.2021.104856.
[PMID] 33839311.
2021
SIRT1 Gene SNP rs932658 Is Associated With Medication‐Related Osteonecrosis of the Jaw
Journal of Bone and Mineral Research.
36(2):347-356
[DOI] 10.1002/jbmr.4185.
[PMID] 32967053.
2020
Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention.
Clinical Pharmacology & Therapeutics.
2020
Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure.
.
7(1):123-129
2020
Association of Factor V Leiden with Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.
Circulation.
July(13)
2020
Association of P2RX7 functional variants with localized aggressive periodontitis.
Journal of periodontal research.
55(1):32-40
[DOI] 10.1111/jre.12682.
[PMID] 31292966.
2020
Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease
The Journal of Clinical Hypertension.
22(11):1987-1992
[DOI] 10.1111/jch.14037.
[PMID] 32951360.
2020
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.
American journal of hypertension.
33(4):316-324
[DOI] 10.1093/ajh/hpz196.
[PMID] 31853537.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
The Pharmacogenomics Journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST☆.
International Journal of Cardiology. Hypertension.
7
[DOI] 10.1016/j.ijchy.2020.100052.
[PMID] 33817619.
2020
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
American journal of hypertension.
33(2)
[DOI] 10.1093/ajh/hpz168.
[PMID] 31891170.
2020
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST)
Journal of Womens Health.
29(2):158-166
2020
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Journal of women's health (2002).
29(2):158-166
[DOI] 10.1089/jwh.2018.7235.
[PMID] 31403360.
2020
Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure.
ESC heart failure.
7(1):123-129
[DOI] 10.1002/ehf2.12534.
[PMID] 31840441.
2020
Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure.
.
7(1):123-129
2019
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease
The Journal of Clinical Hypertension.
21(1):91-101
[DOI] 10.1111/jch.13429.
[PMID] 30427124.
2019
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.
Circulation-Genomic and Precision Medicine.
12(4)
[DOI] 10.1161/CIRCGEN.119.002471.
[PMID] 30897348.
2019
CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(8):1842-1850
[DOI] 10.1038/s41436-018-0431-8.
[PMID] 30670877.
2019
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
131:93-98
[DOI] 10.1016/j.ejps.2019.02.013.
[PMID] 30753892.
2019
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-53345-5.
[PMID] 31754133.
2019
Genome-wide association analysis of common genetic variants of resistant hypertension.
The pharmacogenomics journal.
19(3):295-304
[DOI] 10.1038/s41397-018-0049-x.
[PMID] 30237584.
2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
Journal of the American Heart Association.
8(16)
[DOI] 10.1161/JAHA.119.013115.
[PMID] 31423876.
2019
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clinical and translational science.
12(5):497-504
[DOI] 10.1111/cts.12643.
[PMID] 31033190.
2019
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers
PLoS One.
14(9)
[DOI] 10.1371/journal.pone.0221957.
[PMID] 31532792.
2019
Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods.
AMIA … Annual Symposium proceedings / AMIA Symposium. AMIA Symposium.
933-941
2019
MADEx: A System for Detecting Medications, Adverse Drug Events, and Their Relations from Clinical Notes.
Drug safety.
42(1):123-133
[DOI] 10.1007/s40264-018-0761-0.
[PMID] 30600484.
2019
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Clinical and translational science.
12(2):172-179
[DOI] 10.1111/cts.12589.
[PMID] 30341969.
2019
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network
Journal of the American Heart Association.
8(9)
[DOI] 10.1161/JAHA.118.011246.
[PMID] 31020929.
2019
Pharmacogenomics of osteonecrosis of the jaw.
Bone.
124:75-82
[DOI] 10.1016/j.bone.2019.04.010.
[PMID] 31022475.
2019
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
American journal of hypertension.
32(7):668-675
[DOI] 10.1093/ajh/hpz022.
[PMID] 30753254.
2019
Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Journal of acquired immune deficiency syndromes (1999. Online).
82(4):421-425
2019
Subsequent Event Risk in Individuals With Established Coronary Heart Disease.
Circulation-Genomic and Precision Medicine.
12(4)
[DOI] 10.1161/CIRCGEN.119.002470.
[PMID] 30896328.
2019
β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.
Journal of clinical pharmacology.
59(11):1462-1470
[DOI] 10.1002/jcph.1443.
[PMID] 31090079.
2018
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.
Frontiers in pharmacology.
9
[DOI] 10.3389/fphar.2018.00752.
[PMID] 30065651.
2018
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC medical genomics.
11(1)
[DOI] 10.1186/s12920-018-0370-x.
[PMID] 29925376.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.
16(1)
[DOI] 10.1186/s12967-018-1469-8.
[PMID] 29642909.
2018
Conflicting Meal Recommendations for Oral Oncology Drugs: Pose Risks to Patient Care?
European Journal of Clinical Pharmacology.
74(6):833-842
[DOI] 10.1007/s00228-018-2439-z.
2018
Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Contemporary clinical trials.
68:7-13
[DOI] 10.1016/j.cct.2018.03.001.
[PMID] 29535047.
2018
Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer.
JAMA oncology.
4(2)
[DOI] 10.1001/jamaoncol.2017.3407.
[PMID] 29098270.
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circulation. Genomic and precision medicine.
11(4)
[DOI] 10.1161/CIRCGEN.117.001854.
[PMID] 29650764.
2018
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
Journal of the American Heart Association.
7(6)
[DOI] 10.1161/JAHA.117.007339.
[PMID] 29523524.
2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.
Journal of the American Heart Association.
7(5)
[DOI] 10.1161/JAHA.117.006463.
[PMID] 29478026.
2018
Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.
The pharmacogenomics journal.
18(1):106-112
[DOI] 10.1038/tpj.2016.67.
[PMID] 27670767.
2018
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
Clinical and translational science.
11(2):175-181
[DOI] 10.1111/cts.12533.
[PMID] 29351371.
2018
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
.
11(2):175-181
2018
Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high‐normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database
The Journal of Clinical Hypertension.
20(4):620-624
[DOI] 10.1111/jch.13247.
[PMID] 29532983.
2018
Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
.
36(2):419-427
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2018
Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.
The American journal of medicine.
131(12):1463-1472.e7
[DOI] 10.1016/j.amjmed.2018.08.005.
[PMID] 30142317.
2018
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.
38(6):356-361
[DOI] 10.1111/scd.12318.
[PMID] 30194738.
2018
SIRT1/HERC4 Locus Associated With Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
33(1):91-98
[DOI] 10.1002/jbmr.3285.
[PMID] 28856724.
2018
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Pharmacogenetics and Genomics.
28(11):251-255
[DOI] 10.1097/FPC.0000000000000353.
[PMID] 30289819.
2018
Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.
Cardiovascular toxicology.
18(2):184-191
[DOI] 10.1007/s12012-017-9429-8.
[PMID] 29022233.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of clinical hypertension (Greenwich, Conn.).
19(12):1301-1308
[DOI] 10.1111/jch.13094.
[PMID] 28940643.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of Clinical Hypertension.
19(12):1301-1308
2017
Colorectal cancer stages transcriptome analysis
PLOS ONE.
12(11)
[DOI] 10.1371/journal.pone.0188697.
[PMID] 29182684.
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Journal of the American Heart Association.
6(11)
[DOI] 10.1161/JAHA.117.006522.
[PMID] 29097388.
2017
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
69(1):51-59
[PMID] 27802415.
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response
Circulation-Cardiovascular Genetics.
10(1)
[DOI] 10.1161/CIRCGENETICS.116.001404.
2017
Long-term clinical response to treatment and maintenance of localized aggressive periodontitis: a cohort study.
Journal of clinical periodontology.
44(2):158-168
[DOI] 10.1111/jcpe.12640.
[PMID] 27767222.
2017
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
Stroke.
48(5):1337-1343
[DOI] 10.1161/STROKEAHA.116.015936.
[PMID] 28351962.
2017
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
Journal of the American Heart Association.
7(1)
[DOI] 10.1161/JAHA.117.006656.
[PMID] 29288159.
2017
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-16343-z.
[PMID] 29167564.
2016
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension (Dallas, Tex. : 1979).
68(3):621-9
[DOI] 10.1161/HYPERTENSIONAHA.116.07328.
[PMID] 27381900.
2016
Ces1P1 Variant-816a > C Is Not Associated With Hepatic Carboxylesterase 1 Expression and Activity or Antihypertensive Effect of Trandolapril
European journal of clinical pharmacology.
72(6):681-687
[DOI] 10.1007/s00228-016-2029-x.
[PMID] 26915813.
2016
Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.
Hypertension (Dallas, Tex. : 1979).
68(5):1110-1114
[PMID] 27620390.
2016
Long-term variability of exhaled nitric oxide measurements.
The journal of allergy and clinical immunology. In practice.
4(1):147-8.e1
[DOI] 10.1016/j.jaip.2015.09.010.
[PMID] 26563669.
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Clinical and translational science.
9(2):114-22
[DOI] 10.1111/cts.12389.
[PMID] 26946962.
2016
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women’s Heart Disease.
Journal of women's health (2002).
25(10):996-1003
[PMID] 27224417.
2016
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics : Official journal of the Metabolomic Society.
12(8)
[DOI] 10.1007/s11306-016-1076-8.
[PMID] 28217400.
2016
Osteonecrosis of the Jaw in the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
31(2):336-40
[DOI] 10.1002/jbmr.2693.
[PMID] 26288087.
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Hypertension (Dallas, Tex. : 1979).
67(3):556-63
[DOI] 10.1161/HYPERTENSIONAHA.115.06345.
[PMID] 26729753.
2016
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.
Metabolomics : Official journal of the Metabolomic Society.
12(10)
[DOI] 10.1007/s11306-016-1098-2.
[PMID] 28217401.
2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
Metabolic syndrome and related disorders.
13(5):195-202
[DOI] 10.1089/met.2014.0132.
[PMID] 25664967.
2015
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Journal of the American Heart Association.
4(6)
[DOI] 10.1161/JAHA.114.001652.
[PMID] 26019129.
2015
Drug induced osteonecrosis of the jaw.
Cancer treatment reviews.
41(5):455-64
[DOI] 10.1016/j.ctrv.2015.04.007.
[PMID] 25913713.
2015
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
PloS one.
10(4)
[DOI] 10.1371/journal.pone.0122726.
[PMID] 25835002.
2015
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
The American journal of medicine.
128(2):137-43
[DOI] 10.1016/j.amjmed.2014.09.028.
[PMID] 25447610.
2015
Pharmacogenomics of Hypertension: a Genome-Wide, Placebo-Controlled Cross-Over Study, Using Four Classes of Antihypertensive Drugs
Journal of the American Heart Association.
4(1)
[DOI] 10.1161/JAHA.114.001521.
[PMID] 25622599.
2015
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Journal of hypertension.
33(11):2278-85
[DOI] 10.1097/HJH.0000000000000714.
[PMID] 26425837.
2015
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Journal of hypertension.
33(6):1301-9
[DOI] 10.1097/HJH.0000000000000541.
[PMID] 25695618.
2014
2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited Results From the Invest Study
Journal of the American College of Cardiology.
64(8):784-793
[DOI] 10.1016/j.jacc.2014.05.044.
[PMID] 25145522.
2014
A Pharmacogenomic Genome-Wide Association Study (Gwas) for New Onset Diabetes (Nod) in the International Verapamil Sr-Trandolapril Study (Invest)
Clinical Pharmacology & Therapeutics.
95(1):S59-S60
2014
A Pharmacogenomic Genome-Wide Association Study for Adverse Cardiovascular Outcomes in the International Verapamil Sr-Trandolapril Study (Invest)
Clinical Pharmacology & Therapeutics.
95(1)
2014
Alteration in Fasting Glucose After Prolonged Treatment With a Thiazide Diuretic
Diabetes Research and Clinical Practice.
104(3):363-369
[DOI] 10.1016/j.diabres.2014.04.004.
[PMID] 24794890.
2014
Baseline predictors of central aortic blood pressure: a PEAR substudy.
Journal of the American Society of Hypertension : JASH.
8(3):152-8
[DOI] 10.1016/j.jash.2013.12.008.
[PMID] 24629400.
2014
Gene-Centric Meta-Analyses for Central Adiposity Traits in Up To 57 412 Individuals of European Descent Confirm Known Loci and Reveal Several Novel Associations
Human Molecular Genetics.
23(9):2498-2510
[DOI] 10.1093/hmg/ddt626.
[PMID] 24345515.
2014
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Journal of internal medicine.
276(5):486-97
[DOI] 10.1111/joim.12215.
[PMID] 24612202.
2014
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Clinical pharmacology and therapeutics.
96(2):175-81
[DOI] 10.1038/clpt.2014.62.
[PMID] 24637943.
2014
Is Diabetes Mellitus-Linked Amino Acid Signature Associated With Beta-Blocker-Induced Impaired Fasting Glucose?
Circulation-Cardiovascular Genetics.
7(2):199-205
[DOI] 10.1161/CIRCGENETICS.113.000421.
[PMID] 24627569.
2014
Large-Scale Gene-Centric Analysis Identifies Polymorphisms for Resistant Hypertension
Journal of the American Heart Association.
3(6)
[DOI] 10.1161/JAHA.114.001398.
[PMID] 25385345.
2014
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
Journal of hypertension.
32(3):635-43
[DOI] 10.1097/HJH.0000000000000051.
[PMID] 24299915.
2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Pharmacotherapy.
34(11):1132-40
[DOI] 10.1002/phar.1483.
[PMID] 25202885.
2014
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy.
34(2):123-30
[DOI] 10.1002/phar.1355.
[PMID] 24122840.
2013
Association Between the Chromosome 9P21 Locus and Angiographic Coronary Artery Disease Burden a Collaborative Meta-Analysis
Journal of the American College of Cardiology.
61(9):957-970
[DOI] 10.1016/j.jacc.2012.10.051.
[PMID] 23352782.
2013
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
The pharmacogenomics journal.
13(3):257-63
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of Cyp2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children
Journal of Pediatrics.
163(3):686-691
[DOI] 10.1016/j.jpeds.2013.03.017.
[PMID] 23623526.
2013
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
The pharmacogenomics journal.
13(5):430-6
[DOI] 10.1038/tpj.2012.34.
[PMID] 22907731.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076984.
[PMID] 24116192.
2013
Genetic Variation in Pear1 Is Associated With Platelet Aggregation and Cardiovascular Outcomes
Circulation-Cardiovascular Genetics.
6(2):184+-92
[DOI] 10.1161/CIRCGENETICS.111.964627.
[PMID] 23392654.
2013
Genomic Association Analysis of Common Variants Influencing Antihypertensive Response To Hydrochlorothiazide
Hypertension.
62(2):391-397
[DOI] 10.1161/HYPERTENSIONAHA.111.00436.
[PMID] 23753411.
2013
Impact of Cyp2D6 Polymorphisms On the Clinical Response and Tolerability of Immediate Release Metoprolol.
Pharmacotherapy.
33
2013
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
PloS one.
8(1)
[DOI] 10.1371/journal.pone.0052062.
[PMID] 23341889.
2013
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Pharmacogenetics and genomics.
23(12):697-705
[DOI] 10.1097/FPC.0000000000000012.
[PMID] 24128935.
2013
Lack of Association of the Hmga1 Ivs5-13Insc Variant With Type 2 Diabetes in An Ethnically Diverse Hypertensive Case Control Cohort
Journal of translational medicine.
11
[DOI] 10.1186/1479-5876-11-12.
[PMID] 23302499.
2013
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
Clinical cardiology.
36(8):442-7
[DOI] 10.1002/clc.22145.
[PMID] 23720247.
2013
Nutrigenetic Response To Omega-3 Fatty Acids in Obese Asthmatics (Nooa): Rationale and Methods
Contemporary Clinical Trials.
34(2):326-335
[DOI] 10.1016/j.cct.2012.12.009.
[PMID] 23298524.
2013
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Hypertension (Dallas, Tex. : 1979).
62(1):48-54
[DOI] 10.1161/HYPERTENSIONAHA.111.00823.
[PMID] 23690342.
2013
Pharmacometabolomics Reveals Racial Differences in Response To Atenolol Treatment
PLoS One.
8(3)
[DOI] 10.1371/journal.pone.0057639.
[PMID] 23536766.
2013
Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease.
Journal of the American Heart Association.
2(4)
[DOI] 10.1161/JAHA.113.000205.
[PMID] 23948642.
2012
Alpha Adducin-1 (Add1)Singlenucleotide Polymorphism (Snp) Associated With New Onset Diabetes Risk With Hydrochlorothiazide (Hctz) Therapy in the International Verapamil Sr Trandolapril Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91
2012
Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose
Clinical Pharmacology & Therapeutics.
91
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics.
91:S59-S60
2012
Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol
American Journal of Hypertension.
25(3):359-365
[DOI] 10.1038/ajh.2011.215.
[PMID] 22089105.
2012
Cholesteryl Ester Transfer Protein (Cetp) Polymorphisms Affect Mrna Splicing, Hdl Levels, and Sex-Dependent Cardiovascular Risk
PLoS One.
7(3)
[DOI] 10.1371/journal.pone.0031930.
[PMID] 22403620.
2012
Chronic pain, perceived stress, and cellular aging: an exploratory study.
Molecular pain.
8
[DOI] 10.1186/1744-8069-8-12.
[PMID] 22325162.
2012
Cyp2C9 Promoter Variable Number Tandem Repeat Polymorphism Regulates Mrna Expression in Human Livers
Drug metabolism and disposition: the biological fate of chemicals.
40(5):884-891
[DOI] 10.1124/dmd.111.044255.
[PMID] 22289258.
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2012
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Hypertension (Dallas, Tex. : 1979).
60(4):957-64
[DOI] 10.1161/HYPERTENSIONAHA.112.198721.
[PMID] 22949529.
2012
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.
Journal of clinical pharmacology.
52(6):837-49
[DOI] 10.1177/0091270011405664.
[PMID] 21642471.
2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circulation. Cardiovascular genetics.
5(6):686-91
[DOI] 10.1161/CIRCGENETICS.112.964080.
[PMID] 23087401.
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Mortality Associated With Angina and Blood Pressure Control Among Hypertensive Patients With Coronary Artery Disease: New Data From Extended Follow-Up of the International Verapamil/Trandolapril Study
Journal of the American College of Cardiology.
59
2012
Mortality Associated With Angina and Blood Pressure Control Among Hypertensive Patients With Coronary Artery Disease: New Data From Extended Follow-Up of the International Verapamil/Trandolapril Study
Journal of the American College of Cardiology.
59
2012
Near-Infrared Background Anisotropies From Diffuse Intrahalo Light of Galaxies
Nature.
490(7421):514-516
[DOI] 10.1038/nature11474.
[PMID] 23099405.
2012
Non-Synonymous Snps in Sele, Selp, and Siglec12 Associate With Cardiovascular (Cv) Outcomes in the International Verapamil Sr-Trandol-April Study Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91:S20-S21
2012
Simple Prediction of Long-Term Mortality Among Hypertensive Patients With Coronary Artery Disease: New Data From An Extended Follow-Up of the International Verapamil-Sr/Trandolapril Study (Invest)
Journal of the American College of Cardiology.
59
2012
Treatment-Resistant Blood Pressure Among Patients With Coronary Artery Disease – Cause for Concern: New Data From the Extended Follow-Up of the International Verapamail Sr-Trandolapril Study (Invest)
Journal of the American College of Cardiology.
59
2012
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
Kidney & blood pressure research.
35(6):477-82
[DOI] 10.1159/000337370.
[PMID] 22688828.
2011
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease.
Circulation. Cardiovascular genetics.
4(2):169-78
[DOI] 10.1161/CIRCGENETICS.110.959296.
[PMID] 21372283.
2011
Genetic and Nongenetic Factors Associated With Warfarin Dose Requirements in Egyptian Patients
Pharmacogenetics and Genomics.
21(3):130-135
[DOI] 10.1097/FPC.0b013e3283436b86.
[PMID] 21228733.
2011
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
International journal of oral and maxillofacial surgery.
40(6):605-11
[DOI] 10.1016/j.ijom.2011.02.002.
[PMID] 21396799.
2011
Genetic Variation in the Calcium Signaling Pathway and Association With Outcomes in Hypertensive Coronary Artery Disease Patients
Clinical Pharmacology & Therapeutics.
89
2011
Genetic Variation in the Calcium Signaling Pathway and Association With Outcomes in Hypertensive Coronary Artery Disease Patients
Clinical Pharmacology & Therapeutics.
89
2011
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
The American journal of medicine.
124(7):614-20
[DOI] 10.1016/j.amjmed.2011.02.025.
[PMID] 21596367.
2011
Influence of G Protein Receptor Kinase 4 (Grk4) Polymorphisms On Blood Pressure Response To the Beta-Blocker Atenolol.
Clinical Pharmacology & Therapeutics.
89
2011
Kcnj1 Snps Are Associated With Increased Fasting Glucose and Risk of New Onset Diabetes During Hctz Therapy
Clinical Pharmacology & Therapeutics.
89
2011
Response To Letter Regarding Article “Chromosome 9P21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease”
Circulation-Cardiovascular Genetics.
4(4)
[DOI] 10.1161/CIRCGENETICS.111.960807.
2010
Aromatase Gene Polymorphisms Are Associated With Survival Among Patients With Cardiovascular Disease in a Sex-Specific Manner
PLoS One.
5(12)
[DOI] 10.1371/journal.pone.0015180.
[PMID] 21170323.
2010
Association Between Melatonin Receptor 1B Single Nucleotide Polymorphisms (Snps) and Response To Antihypertensive Drugs.
Clinical Pharmacology & Therapeutics.
87
2010
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy.
The American journal of medicine.
123(8):719-26
[DOI] 10.1016/j.amjmed.2010.02.014.
[PMID] 20670726.
2010
Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage- Gated Calcium Channel ( Cacnb2) With Outcomes in Hypertensive Coronary Artery Disease ( Cad) Patients.
Clinical Pharmacology & Therapeutics.
87
2010
Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage- Gated Calcium Channel (Cacnb2) With Outcomes in Hypertensive Coronary Artery Disease (Cad) Patients.
Clinical Pharmacology & Therapeutics.
87
2010
Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response To Atenolol and Hydrochlorthiazide
Journal of Clinical Hypertension.
12(1):14-21
[DOI] 10.1111/j.1751-7176.2009.00185.x.
[PMID] 20047624.
2010
Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]).
The American journal of cardiology.
106(4):498-503
[DOI] 10.1016/j.amjcard.2010.03.056.
[PMID] 20691307.
2010
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Circulation. Cardiovascular genetics.
3(6):548-55
[DOI] 10.1161/CIRCGENETICS.110.957654.
[PMID] 21156931.
2010
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension (Dallas, Tex. : 1979).
55(1):61-8
[DOI] 10.1161/HYPERTENSIONAHA.109.139592.
[PMID] 19917874.
2010
New-Onset Diabetes Risk Associated With Antihypertensive Therapy in Hypertensive Coronary Artery Disease Patients Is Modified By a Single Nucleotide Polymorphism (Snp) in the L-Type Calcium Channel (Ltcc)
Clinical Pharmacology & Therapeutics.
87
2010
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Hypertension (Dallas, Tex. : 1979).
55(1):48-53
[DOI] 10.1161/HYPERTENSIONAHA.109.142240.
[PMID] 19996066.
2010
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
JAMA.
304(1):61-8
[DOI] 10.1001/jama.2010.884.
[PMID] 20606150.
2009
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Circulation. Cardiovascular genetics.
2(4):362-70
[DOI] 10.1161/CIRCGENETICS.109.857839.
[PMID] 20031608.
2009
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.
Hypertension (Dallas, Tex. : 1979).
53(4):624-30
[DOI] 10.1161/HYPERTENSIONAHA.108.111542.
[PMID] 19237684.
2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Clinical pharmacology and therapeutics.
86(5):533-9
[DOI] 10.1038/clpt.2009.101.
[PMID] 19571804.
2009
Incident Or Continued Angina During Hypertension Treatment Is Associated With Increased Risk of Death, Mi, Or Stroke Among Patients With Known Cad: a Substudy of the International Verapamil/Trandolapril Study (Invest)
Circulation.
120:S440-S441
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy.
29(10):1157-65
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Long-Term Mortality Associated With New Onset Diabetes in Hypertensive Cad Patients Following Exposure To Antihypertensive Medications: Findings From the International Verapamail Sr-Trandolapril Study (Invest)
Journal of the American College of Cardiology.
53
2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
American heart journal.
157(3):442-9
[DOI] 10.1016/j.ahj.2008.11.018.
[PMID] 19249413.
2009
Promoter Polymorphisms in Ace (Angiotensin I-Converting Enzyme) Associated With Clinical Outcomes in Hypertension
Clinical Pharmacology & Therapeutics.
85(1):36-44
[DOI] 10.1038/clpt.2008.194.
[PMID] 18946466.
2009
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Clinical cardiology.
32(11):627-32
[DOI] 10.1002/clc.20501.
[PMID] 19711440.
2008
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
American heart journal.
156(2):397-404
[DOI] 10.1016/j.ahj.2008.03.007.
[PMID] 18657677.
2008
Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease.
Archives of internal medicine.
168(7):763-70
[DOI] 10.1001/archinte.168.7.763.
[PMID] 18413560.
2008
B1-Adrenergic Receptor Polymorphism Predicts Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Artery Disease
Journal of the American College of Cardiology.
51
2008
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Clinical pharmacology and therapeutics.
84(6):715-21
[DOI] 10.1038/clpt.2008.139.
[PMID] 18615004.
2008
Cacnaic Polymorphisms and Cardiovascular Outcomes in the International Verapamil Sr/Trandolapril Study-Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Diabetes Risk Associated With Beta 1-Adrenergic Receptor Polymorphisms Differs By Antihypertensive Drug Therapy: Results From the International Verapamil Sr/Trandolapril Study – Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Novel Promoter Polymorphisms in Angiotensin-I Converting Enzyme (Ace) Associated With Clinical Outcomes in Hypertensive Coronary Artery Disease (Cad) Patients.
Clinical Pharmacology & Therapeutics.
83
2007
Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.
Clinical pharmacology and therapeutics.
81(3):386-91
[PMID] 17339868.
2007
Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure.
Journal of cardiac failure.
13(8):656-62
[PMID] 17923358.
2007
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
The American journal of cardiology.
99(11):1549-54
[PMID] 17531579.
2007
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Pharmacogenetics and genomics.
17(9):719-29
[PMID] 17700361.
2007
Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit.
Pharmacogenetics and genomics.
17(4):267-75
[PMID] 17496725.
2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Pharmacogenetics and genomics.
17(4):277-82
[PMID] 17496726.
2006
Actin binding activity of subunit B of vacuolar H+-ATPase is involved in its targeting to ruffled membranes of osteoclasts.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
21(5):714-21
[PMID] 16734386.
2006
Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat.
Experimental neurology.
200(2):371-7
[PMID] 16780838.
2004
A statistical model for functional mapping of quantitative trait loci regulating drug response.
The pharmacogenomics journal.
4(5):315-21
[PMID] 15263889.
2004
Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia.
Brain research. Brain research protocols.
14(1):18-24
[PMID] 15519948.
2002
Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain.
Experimental neurology.
176(1):66-74
[PMID] 12093083.
Grants
Sep 2021
– Sep 2023
Toward a Precision Medicine Approach to Medication-Related Osteonecrosis of the Jaw
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDCR
Aug 2021
ACTIVE
A Multi-omics evaluation of Carfilzomib-related Cardiotoxicity
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Jun 2021
– Aug 2021
Replication of GenHAT GWAS signals in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and Genetic Epidemiology of Responses to Antihypertensives (GERA)
Role: Co-Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM
via NATL INST OF HLTH
Jul 2020
ACTIVE
Precision antiplatelet therapy after percutaneous coronary intervention
Role: Other
Funding: NATL INST OF HLTH NHLBI
Sep 2018
ACTIVE
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Role: Co-Investigator
Funding: NATL INST OF HLTH NICHD
Aug 2018
ACTIVE
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Role: Co-Investigator
Funding: NATL INST OF HLTH NICHD
Apr 2017
ACTIVE
HSC COM Matching Commitment
Role: Project Manager
Funding: UNIV OF FLORIDA
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jul 2016
– Sep 2020
A stem cell tactic to promote personalized medicine
Role: Project Manager
Funding: NATL INST OF HLTH NIGMS
Jun 2016
– Aug 2018
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Role: Co-Investigator
Funding: NATL INST OF HLTH NICHD
Oct 2015
– Mar 2019
OneFlorida Clinical Research Consortium Phase II
Role: Other
Funding: PATIENT-CENTERED OUTCOMES RES INST
Apr 2015
– Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jun 2014
– Nov 2021
Mechanisms and Treatment Response of Aggressive Periodontitis in Children
Role: Project Manager
Funding: NATL INST OF HLTH NIDCR
Education
Ph.D.
2004
·
University of Florida
M.S.
2003
·
University of Florida
M.S.
1999
·
West China University of Medical Sciences
Contact Details
Phones:
- Business:
- (352) 273-6297
Emails:
- Business:
- gong@cop.ufl.edu
Addresses:
- Business Mailing:
-
UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER
PO BOX 100486
1600 SW ARCHER ROAD
GAINESVILLE FL 326100486 - Business Street:
-
MSB PG-27
1345 CENTER DR
GAINESVILLE FL 32610